Logo image of ORGO

ORGANOGENESIS HOLDINGS INC (ORGO) Stock Fundamental Analysis

USA - NASDAQ:ORGO - US68621F1021 - Common Stock

4.08 USD
+0.04 (+0.99%)
Last: 10/20/2025, 8:09:00 PM
4.08 USD
0 (0%)
After Hours: 10/20/2025, 8:09:00 PM
Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to ORGO. ORGO was compared to 534 industry peers in the Biotechnology industry. ORGO has only an average score on both its financial health and profitability. While showing a medium growth rate, ORGO is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

4

1. Profitability

1.1 Basic Checks

ORGO had negative earnings in the past year.
ORGO had a negative operating cash flow in the past year.
Of the past 5 years ORGO 4 years were profitable.
ORGO had a positive operating cash flow in each of the past 5 years.
ORGO Yearly Net Income VS EBIT VS OCF VS FCFORGO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M

1.2 Ratios

With an excellent Return On Assets value of -3.38%, ORGO belongs to the best of the industry, outperforming 87.83% of the companies in the same industry.
Looking at the Return On Equity, with a value of -4.32%, ORGO belongs to the top of the industry, outperforming 89.89% of the companies in the same industry.
Industry RankSector Rank
ROA -3.38%
ROE -4.32%
ROIC N/A
ROA(3y)1.45%
ROA(5y)6.32%
ROE(3y)2.46%
ROE(5y)11.67%
ROIC(3y)N/A
ROIC(5y)N/A
ORGO Yearly ROA, ROE, ROICORGO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50 -100

1.3 Margins

ORGO's Operating Margin has declined in the last couple of years.
The Gross Margin of ORGO (74.58%) is better than 83.15% of its industry peers.
In the last couple of years the Gross Margin of ORGO has remained more or less at the same level.
ORGO does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 74.58%
OM growth 3Y-34.07%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.17%
GM growth 5Y1.4%
ORGO Yearly Profit, Operating, Gross MarginsORGO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 60

More info and screens

5

2. Health

2.1 Basic Checks

ORGO does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ORGO has been reduced compared to 1 year ago.
The number of shares outstanding for ORGO has been increased compared to 5 years ago.
The debt/assets ratio for ORGO has been reduced compared to a year ago.
ORGO Yearly Shares OutstandingORGO Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
ORGO Yearly Total Debt VS Total AssetsORGO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

ORGO has an Altman-Z score of 4.20. This indicates that ORGO is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of ORGO (4.20) is better than 72.85% of its industry peers.
ORGO has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
ORGO has a Debt to Equity ratio (0.00) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 4.2
ROIC/WACCN/A
WACC9.75%
ORGO Yearly LT Debt VS Equity VS FCFORGO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M 300M

2.3 Liquidity

ORGO has a Current Ratio of 3.95. This indicates that ORGO is financially healthy and has no problem in meeting its short term obligations.
ORGO has a Current ratio (3.95) which is comparable to the rest of the industry.
A Quick Ratio of 3.45 indicates that ORGO has no problem at all paying its short term obligations.
ORGO has a Quick ratio (3.45) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 3.95
Quick Ratio 3.45
ORGO Yearly Current Assets VS Current LiabilitesORGO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

5

3. Growth

3.1 Past

ORGO shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -225.00%.
The earnings per share for ORGO have been decreasing by -37.90% on average. This is quite bad
The Revenue has decreased by -4.20% in the past year.
ORGO shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 13.05% yearly.
EPS 1Y (TTM)-225%
EPS 3Y-37.9%
EPS 5YN/A
EPS Q2Q%-350%
Revenue 1Y (TTM)-4.2%
Revenue growth 3Y0.98%
Revenue growth 5Y13.05%
Sales Q2Q%-22.44%

3.2 Future

The Earnings Per Share is expected to grow by 46.59% on average over the next years. This is a very strong growth
ORGO is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 12.92% yearly.
EPS Next Y-136%
EPS Next 2Y36.38%
EPS Next 3Y46.59%
EPS Next 5YN/A
Revenue Next Year4.04%
Revenue Next 2Y14.25%
Revenue Next 3Y12.92%
Revenue Next 5YN/A

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
ORGO Yearly Revenue VS EstimatesORGO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 200M 400M 600M
ORGO Yearly EPS VS EstimatesORGO Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 0.2 -0.2 0.4 -0.4 0.6

More info and screens

3

4. Valuation

4.1 Price/Earnings Ratio

ORGO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
With a Price/Forward Earnings ratio of 12.90, ORGO is valued correctly.
Based on the Price/Forward Earnings ratio, ORGO is valued cheaper than 96.07% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of ORGO to the average of the S&P500 Index (23.18), we can say ORGO is valued slightly cheaper.
Industry RankSector Rank
PE N/A
Fwd PE 12.9
ORGO Price Earnings VS Forward Price EarningsORGO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 -50

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, ORGO is valued cheaper than 89.89% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 139.21
ORGO Per share dataORGO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3

4.3 Compensation for Growth

A more expensive valuation may be justified as ORGO's earnings are expected to grow with 46.59% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.38%
EPS Next 3Y46.59%

More info and screens

0

5. Dividend

5.1 Amount

ORGO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ORGANOGENESIS HOLDINGS INC

NASDAQ:ORGO (10/20/2025, 8:09:00 PM)

After market: 4.08 0 (0%)

4.08

+0.04 (+0.99%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-07 2025-08-07/amc
Earnings (Next)11-06 2025-11-06/amc
Inst Owners55.08%
Inst Owner Change2.99%
Ins Owners31.49%
Ins Owner Change0.23%
Market Cap517.59M
Analysts85
Price Target8.16 (100%)
Short Float %16.11%
Short Ratio14.2
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-73%
Min EPS beat(2)-73%
Max EPS beat(2)-73%
EPS beat(4)2
Avg EPS beat(4)278.21%
Min EPS beat(4)-73%
Max EPS beat(4)688.24%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-5.3%
Min Revenue beat(2)-6.36%
Max Revenue beat(2)-4.23%
Revenue beat(4)2
Avg Revenue beat(4)1.61%
Min Revenue beat(4)-6.36%
Max Revenue beat(4)13.3%
Revenue beat(8)4
Avg Revenue beat(8)0.38%
Revenue beat(12)5
Avg Revenue beat(12)0.07%
Revenue beat(16)6
Avg Revenue beat(16)-0.09%
PT rev (1m)0%
PT rev (3m)14.29%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-26.67%
EPS NY rev (1m)-200%
EPS NY rev (3m)-100%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-3.64%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.39%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 12.9
P/S 1.21
P/FCF N/A
P/OCF N/A
P/B 1.43
P/tB 1.61
EV/EBITDA 139.21
EPS(TTM)-0.05
EYN/A
EPS(NY)0.32
Fwd EY7.75%
FCF(TTM)-0.37
FCFYN/A
OCF(TTM)-0.26
OCFYN/A
SpS3.39
BVpS2.85
TBVpS2.54
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -3.38%
ROE -4.32%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 74.58%
FCFM N/A
ROA(3y)1.45%
ROA(5y)6.32%
ROE(3y)2.46%
ROE(5y)11.67%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)4.79%
ROCE(5y)9.27%
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y-34.07%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.17%
GM growth 5Y1.4%
F-Score3
Asset Turnover0.93
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA 0.03
Cap/Depr 74.48%
Cap/Sales 3.07%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.95
Quick Ratio 3.45
Altman-Z 4.2
F-Score3
WACC9.75%
ROIC/WACCN/A
Cap/Depr(3y)177.81%
Cap/Depr(5y)208.05%
Cap/Sales(3y)5.07%
Cap/Sales(5y)5.42%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-225%
EPS 3Y-37.9%
EPS 5YN/A
EPS Q2Q%-350%
EPS Next Y-136%
EPS Next 2Y36.38%
EPS Next 3Y46.59%
EPS Next 5YN/A
Revenue 1Y (TTM)-4.2%
Revenue growth 3Y0.98%
Revenue growth 5Y13.05%
Sales Q2Q%-22.44%
Revenue Next Year4.04%
Revenue Next 2Y14.25%
Revenue Next 3Y12.92%
Revenue Next 5YN/A
EBIT growth 1Y-221.35%
EBIT growth 3Y-33.42%
EBIT growth 5YN/A
EBIT Next Year410.89%
EBIT Next 3Y109.75%
EBIT Next 5YN/A
FCF growth 1Y-140.26%
FCF growth 3Y-48.6%
FCF growth 5YN/A
OCF growth 1Y-297.24%
OCF growth 3Y-38.8%
OCF growth 5YN/A